Zeo ScientifiX, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Zeo ScientifiX, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | $5.20M | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | $4.62M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $4.56M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $6.49M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $5.60M | Feb 14, 2023 |
| FY2021 | Oct 31, 2020 | $3.06M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $1.70M | Feb 8, 2021 |
| FY2019 | Oct 31, 2018 | $964.5K | Oct 16, 2020 |
| FY2018 | Oct 31, 2017 | $569.8K | Mar 6, 2020 |
| FY2017 | Oct 31, 2016 | $184.9K | Nov 1, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Oct 31, 2020 | $95.5K | Feb 8, 2021 |
| FY2020 | Oct 31, 2019 | $71.7K | Feb 8, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | $4.27M | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | $3.78M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $4.05M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $5.74M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $5.05M | Feb 14, 2023 |
| FY2021 | Oct 31, 2020 | $2.66M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $1.40M | Feb 8, 2021 |
| FY2019 | Oct 31, 2018 | $755.2K | Oct 16, 2020 |
| FY2018 | Oct 31, 2017 | $409.2K | Mar 6, 2020 |
| FY2017 | Oct 31, 2016 | $90.5K | Nov 1, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | ($5.52M) | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | ($4.71M) | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | ($6.99M) | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | ($8.90M) | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | ($12.76M) | Feb 14, 2023 |
| FY2021 | Oct 31, 2020 | ($12.58M) | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | ($1.74M) | Feb 8, 2021 |
| FY2019 | Oct 31, 2018 | ($3.46M) | Oct 16, 2020 |
| FY2018 | Oct 31, 2017 | ($8.97M) | Mar 6, 2020 |
| FY2017 | Oct 31, 2016 | ($1.25M) | Nov 1, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | ($5.39M) | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | ($5.32M) | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | ($6.77M) | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | ($8.84M) | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | ($12.74M) | Feb 14, 2023 |
| FY2021 | Oct 31, 2020 | ($12.44M) | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | ($1.78M) | Feb 8, 2021 |
| FY2019 | Oct 31, 2018 | ($3.49M) | Oct 16, 2020 |
| FY2018 | Oct 31, 2017 | ($8.64M) | Mar 6, 2020 |
| FY2017 | Oct 31, 2016 | ($1.04M) | Nov 1, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | $100.0K | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | $164.0K | Jan 29, 2026 |
| FY2023 | Oct 31, 2023 | $922.7K | Jan 29, 2024 |
| FY2023 | Oct 31, 2022 | $791.3K | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $1.12M | Feb 14, 2023 |
| FY2021 | Oct 31, 2020 | $233.5K | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $54.9K | Feb 8, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | ($718.0K) | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | ($1.45M) | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | ($2.20M) | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | ($3.17M) | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | ($2.68M) | Feb 14, 2023 |
| FY2021 | Oct 31, 2020 | ($1.81M) | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | ($565.5K) | Feb 8, 2021 |
| FY2019 | Oct 31, 2018 | ($512.0K) | Oct 16, 2020 |
| FY2018 | Oct 31, 2017 | ($881.5K) | Mar 6, 2020 |
| FY2017 | Oct 31, 2016 | ($548.2K) | Nov 1, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | $23.0K | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $26.0K | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $824.7K | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $424.7K | Feb 14, 2023 |
| FY2021 | Oct 31, 2020 | $138.7K | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $32.7K | Feb 8, 2021 |
| FY2019 | Oct 31, 2018 | $4.6K | Oct 16, 2020 |
| FY2018 | Oct 31, 2017 | $45.1K | Mar 6, 2020 |
| FY2017 | Oct 31, 2016 | $26.3K | Nov 1, 2018 |
| FY2016 | Oct 31, 2015 | $1.7K | Jul 7, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | $1.53M | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | $1.64M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $2.78M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $6.20M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $1.93M | Feb 14, 2023 |
| FY2021 | Oct 31, 2020 | $1.33M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | $649.1K | Feb 8, 2021 |
| FY2019 | Oct 31, 2018 | $117.0K | Oct 16, 2020 |
| FY2018 | Oct 31, 2017 | $376.8K | Mar 6, 2020 |
| FY2017 | Oct 31, 2016 | $69.9K | Nov 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | $2.95M | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | $3.30M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | $4.02M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | $4.31M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | $4.60M | Feb 14, 2023 |
| FY2021 | Oct 31, 2020 | $2.73M | Feb 14, 2022 |
| FY2016 | Oct 31, 2016 | $853.0K | Jul 7, 2017 |
| FY2016 | Oct 31, 2015 | $139.7K | Jul 7, 2017 |
| FY2015 | Oct 31, 2014 | $63.2K | Jun 22, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | ($1.42M) | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | ($1.65M) | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | ($1.24M) | Jan 29, 2026 |
| FY2024 | Oct 31, 2022 | $1.89M | Jan 29, 2025 |
| FY2023 | Oct 31, 2021 | ($2.67M) | Jan 29, 2024 |
| FY2022 | Oct 31, 2020 | ($1.39M) | Feb 14, 2023 |
| FY2021 | Oct 31, 2019 | ($1.56M) | Feb 14, 2022 |
| FY2019 | Oct 31, 2018 | ($1.26M) | Oct 16, 2020 |
| FY2018 | Oct 31, 2017 | ($3.56M) | Mar 6, 2020 |
| FY2017 | Oct 31, 2016 | ($783.1K) | Nov 1, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | ($67.73M) | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | ($62.21M) | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | ($57.51M) | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | ($50.52M) | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | ($41.62M) | Feb 14, 2023 |
| FY2021 | Oct 31, 2020 | ($28.87M) | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | ($16.29M) | Feb 8, 2021 |
| FY2019 | Oct 31, 2018 | ($14.55M) | Oct 16, 2020 |
| FY2018 | Oct 31, 2017 | ($11.09M) | Mar 6, 2020 |
| FY2017 | Oct 31, 2016 | ($2.11M) | Nov 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Oct 31, 2021 | $108.6K | Feb 14, 2022 |
| FY2021 | Oct 31, 2020 | $590.8K | Feb 14, 2022 |
| FY2021 | Oct 31, 2019 | $132.6K | Feb 14, 2022 |
| FY2020 | Oct 31, 2018 | $43.0K | Feb 8, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | 0 | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | 0 | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | 0 | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | (1) | Jan 29, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | 0 | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | 0 | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | 0 | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | (1) | Jan 29, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Oct 31, 2025 | 6.75M | Jan 29, 2026 |
| FY2024 | Oct 31, 2024 | 6.34M | Jan 29, 2026 |
| FY2024 | Oct 31, 2023 | 7.28M | Jan 29, 2025 |
| FY2023 | Oct 31, 2022 | 7.40M | Jan 29, 2024 |
| FY2022 | Oct 31, 2021 | 1.13B | Feb 14, 2023 |
| FY2021 | Oct 31, 2020 | 939.94M | Feb 14, 2022 |
| FY2020 | Oct 31, 2019 | 502.94M | Feb 8, 2021 |
| FY2019 | Oct 31, 2018 | 436.49M | Oct 16, 2020 |
| FY2018 | Oct 31, 2017 | 111.46M | Mar 6, 2020 |
| FY2017 | Oct 31, 2016 | 104.21M | Nov 1, 2018 |